UNITED THERAPEUTICS Corp
UTHRNasdaq
$535.67
↑ +1.3%Jul 17 close · end-of-day
Price
1Y↑ +79.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$25.3B
Enterprise Value
$23.1B
P/E
19.8
P/S
8.0
P/B
4.3
EV/EBITDA
15.2
PEG
0.9
FCF Yield
4.0%
Dividend Yield
—
Revenue (TTM)
$3.2B
Net Income (TTM)
$1.3B
Free Cash Flow (TTM)
$1.0B
Gross Margin
86.6%
Operating Margin
45.3%
Net Margin
40.6%
ROE
21.8%
ROIC
30.7%
Debt / Equity
—
Net Cash
$2.2B
Return 1Y
+80.2%
Company profile
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise. Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- CEO
- Martine A. Rothblatt
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 980
- Headquarters
- Maryland
- Website
- unither.com
Management & directors
- Mahon Paul AEVP & GENERAL COUNSEL
- Rothblatt Martine AChairperson & CEO
- Edgemond JamesCFO AND TREASURER
- Benkowitz MichaelPRESIDENT AND COO
Roles derived from SEC Form 4 filings.
Earnings
UTHR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$781.5M↓ -1.6%
Diluted EPS$5.82↓ -12.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.5B | $1.7B | $1.9B | $2.3B | $2.9B | $3.2B |
| Gross profit | $1.4B | $1.6B | $1.8B | $2.1B | $2.6B | $2.8B |
| Operating income | $593.6M | $555.9M | $979.7M | $1.2B | $1.4B | $1.5B |
| Net income | — | $475.8M | $727.3M | $984.8M | $1.2B | $1.3B |
| Diluted EPS | $11.54 | $10.06 | $15.00 | $19.81 | $24.64 | $27.86 |
| Operating cash flow | $755.7M | $598.2M | $802.5M | $978.0M | $1.3B | $1.6B |
| Free cash flow | $696.4M | $477.4M | $663.7M | $747.6M | $1.1B | $1.0B |
| Gross margin | 92.7% | 92.7% | 92.2% | 88.9% | 89.2% | 87.9% |
| Operating margin | 40.0% | 33.0% | 50.6% | 50.9% | 47.9% | 46.9% |
| Net margin | — | 28.2% | 37.6% | 42.3% | 41.5% | 41.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $714.9M | $748.9M | $735.9M | $794.4M | $798.6M | $799.5M | $790.2M | $781.5M |
| Gross profit | $637.1M | $665.8M | $660.0M | $701.9M | $711.0M | $698.6M | $686.8M | $648.1M |
| Operating income | $319.9M | $343.1M | $357.7M | $382.8M | $364.5M | $388.5M | $356.7M | $325.8M |
| Net income | $278.1M | $309.1M | $301.3M | $322.2M | $309.5M | $338.7M | $364.3M | $274.9M |
| Diluted EPS | $5.85 | $6.39 | $6.23 | $6.63 | $6.41 | $7.16 | $7.66 | $5.82 |
| Operating cash flow | $232.2M | $377.2M | $341.2M | $461.2M | $191.7M | $562.1M | $346.2M | $463.3M |
| Free cash flow | $187.1M | $300.7M | $254.5M | $386.3M | $129.5M | $351.6M | $173.3M | $362.5M |
| Gross margin | 89.1% | 88.9% | 89.7% | 88.4% | 89.0% | 87.4% | 86.9% | 82.9% |
| Operating margin | 44.7% | 45.8% | 48.6% | 48.2% | 45.6% | 48.6% | 45.1% | 41.7% |
| Net margin | 38.9% | 41.3% | 40.9% | 40.6% | 38.8% | 42.4% | 46.1% | 35.2% |
Company news
Jul 15, 2026
Jul 12, 2026
Jul 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 3,279 | $534.21 | $1.8M | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 3,057 | $529.46 | $1.6M | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Option exercise | 9,500 | $135.42 | $1.3M | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Option exercise | 8,300 | $146.03 | $1.2M | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 1,924 | $530.14 | $1.0M | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 1,519 | $534.99 | $812,648.44 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 1,400 | $528.42 | $739,782.96 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 1,198 | $534.31 | $640,100.62 | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 1,041 | $535.88 | $557,850.87 | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 861 | $531.97 | $458,025.48 | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 800 | $532.94 | $426,351.52 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 720 | $535.20 | $385,342.42 | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 600 | $527.60 | $316,557.00 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 520 | $532.14 | $276,711.50 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 440 | $533.28 | $234,644.39 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 150 | $536.29 | $80,443.07 | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 120 | $529.81 | $63,577.20 | filing |
| 2026-07-16 | MAHON PAUL A· EVP & GENERAL COUNSEL | Sale | 80 | $536.85 | $42,948.21 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 80 | $527.31 | $42,185.08 | filing |
| 2026-07-16 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 11 | $537.11 | $5,908.21 | filing |
| 2026-07-15 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 3,295 | $531.97 | $1.8M | filing |
| 2026-07-15 | ROTHBLATT MARTINE A· Chairperson & CEO | Option exercise | 7,782 | $135.42 | $1.1M | filing |
| 2026-07-15 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 1,044 | $531.03 | $554,390.62 | filing |
| 2026-07-15 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 825 | $533.08 | $439,790.75 | filing |
| 2026-07-15 | ROTHBLATT MARTINE A· Chairperson & CEO | Sale | 800 | $532.06 | $425,647.44 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.